Invitation to presentation of BioArctic’s Interim Report for the period January - September 2021 on October 21 at 9.30 a.m. CET

Stockholm, Sweden, October 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 on Thursday, October 21, 2021, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on October 21, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Interim Report for the period January – September 2021, followed by a Q&A-session. 

To attend, please dial-in at one of the numbers below, from:
Sweden: +46 8 505 583 69 
Denmark: +45 781 501 08 
Germany: +49 692 222 391 66 
The Netherlands: +31 207 219 496 
Norway: +47 239 639 38 
Switzerland: +41 225 675 632 
UK: + 44 333 300 9266 
US: + 1 646 722 4957 

Webcast: https://tv.streamfabriken.com/bioarctic-q3-2021

The webcast will also be available on demand on BioArctic’s corporate website https://www.bioarctic.se/en/section/investors/presentations/ after the presentation.

---

This information was submitted for publication at 11:00 a.m. CET on October 11, 2021.

For further information, please contact: 
Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB 
E-mail: oskar.bosson@bioarctic.se 
Phone: +46 70 410 71 80 

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.